2 Information about Xeomin (botulinum neurotoxin type A)

Information about Xeomin (botulinum neurotoxin type A)

Marketing authorisation indication

Xeomin (botulinum neurotoxin type A, Merz) is intended for 'chronic sialorrhoea due to neurological disorders in adults'.

Dosage in the marketing authorisation

A reconstituted solution at a concentration of 5 units/0.1 ml should be used.

Xeomin is injected into the parotid and submandibular glands on both sides (4 injections per treatment in total). The dose is divided in a ratio of 3:2 between the parotid and submandibular glands as follows:

  • parotid glands: 30 units per side, 0.6 ml per injection

  • submandibular glands: 20 units per side, 0.4 ml per injection.

The injection site should be close to the centre of the gland.

The recommended dose per treatment session is 100 units. This maximum dose should not be exceeded.

Treatment intervals should be determined based on the actual clinical need of the individual patient.

Repeat treatment more frequent than every 16 weeks is not recommended.

Because of unit differences in the potency assay, unit doses for Xeomin are not interchangeable with those for other preparations of botulinum toxin type A.


£129.90 per 100‑unit powder for solution for injection vial (excluding VAT; BNF accessed online July 2019).

The company has a commercial arrangement. This makes Xeomin available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)